Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Post FY2024 Earnings of $1.39 Per Share, Jefferies Financial Group Forecasts
Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Post FY2024 Earnings of $1.39 Per Share, Jefferies Financial Group Forecasts
Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Equities researchers at Jefferies Financial Group reduced their FY2024 EPS estimates for shares of Global Blood Therapeutics in a research note issued on Monday, August 8th. Jefferies Financial Group analyst A. Tewari now forecasts that the company will earn $1.39 per share for the year, down from their prior forecast of $1.44. The consensus estimate for Global Blood Therapeutics' current full-year earnings is ($4.65) per share. Jefferies Financial Group also issued estimates for Global Blood Therapeutics' FY2025 earnings at $3.44 EPS and FY2026 earnings at $5.13 EPS.
全球血液治疗公司(纳斯达克:GBT-GET评级)-杰富瑞金融集团的股票研究人员在8月8日星期一发布的一份研究报告中下调了他们对全球血液治疗公司股票2024财年每股收益的估计。杰富瑞金融集团分析师A.Tewari现在预测,该公司今年的每股收益为1.39美元,低于此前预测的1.44美元。对全球血液治疗公司目前全年收益的普遍估计为每股4.65美元。杰富瑞金融集团还发布了对全球血液治疗公司2025财年每股收益3.44美元和2026财年每股收益5.13美元的估计。
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.07). Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The business had revenue of $71.55 million during the quarter, compared to analyst estimates of $64.39 million. During the same quarter in the prior year, the firm posted ($1.12) earnings per share.
全球血液治疗公司(纳斯达克:GBT-GET评级)最近一次发布季度收益数据是在8月8日星期一。该公司公布了本季度每股收益(EPS)(1.26美元),低于普遍预期的(1.19美元)和(0.07美元)。环球血液治疗公司的净利润率为负146.82%,净资产回报率为负129.74%。该业务本季度营收为7155万美元,而分析师预期为6439万美元。去年同期,该公司公布的每股收益为1.12美元。
Global Blood Therapeutics Price Performance
全球血液治疗药物价格表现
Shares of NASDAQ GBT opened at $66.84 on Wednesday. Global Blood Therapeutics has a fifty-two week low of $21.65 and a fifty-two week high of $73.02. The company has a debt-to-equity ratio of 4.34, a quick ratio of 7.74 and a current ratio of 8.52. The stock has a fifty day moving average of $33.72 and a 200-day moving average of $31.60. The stock has a market cap of $4.35 billion, a PE ratio of -13.72 and a beta of 0.83.
周三,纳斯达克GBT的股价开盘报66.84美元。全球血液治疗公司的股价跌至52周低点21.65美元和52周高点73.02美元。该公司的负债权益比率为4.34,速动比率为7.74,流动比率为8.52。该股的50日移动均线为33.72美元,200日移动均线为31.60美元。该股市值为43.5亿美元,市盈率为-13.72倍,贝塔系数为0.83。
Insider Buying and Selling
内幕买卖
In related news, Director Philip A. Pizzo sold 1,260 shares of the company's stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total transaction of $34,335.00. Following the completion of the transaction, the director now owns 9,112 shares in the company, valued at approximately $248,302. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 4.90% of the company's stock.
在相关新闻中,董事菲利普·A·皮佐在一笔日期为6月21日(星期二)的交易中出售了1,260股该公司股票。这些股票以27.25美元的平均价格出售,总成交额为34,335.00美元。交易完成后,董事现在拥有该公司9,112股,价值约248,302美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过美国证券交易委员会网站访问该文件。内部人士持有该公司4.90%的股份。
Institutional Trading of Global Blood Therapeutics
全球血液治疗的制度性交易
Hedge funds have recently bought and sold shares of the business. SkyView Investment Advisors LLC grew its stake in shares of Global Blood Therapeutics by 587.2% in the 1st quarter. SkyView Investment Advisors LLC now owns 804 shares of the company's stock valued at $28,000 after buying an additional 687 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Global Blood Therapeutics by 75.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock worth $52,000 after purchasing an additional 650 shares during the period. Advisor Group Holdings Inc. boosted its position in shares of Global Blood Therapeutics by 31.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company's stock worth $55,000 after purchasing an additional 450 shares during the period. Lazard Asset Management LLC boosted its position in shares of Global Blood Therapeutics by 31.4% during the 4th quarter. Lazard Asset Management LLC now owns 2,579 shares of the company's stock worth $75,000 after purchasing an additional 617 shares during the period. Finally, Wedbush Securities Inc. purchased a new position in shares of Global Blood Therapeutics during the 2nd quarter worth approximately $207,000.
对冲基金最近买卖了该公司的股票。第一季度,Skyview Investment Advisors LLC在全球血液治疗公司的股份增加了587.2%。Skyview Investment Advisors LLC现在拥有804股该公司股票,价值2.8万美元,在此期间又购买了687股。NISA Investment Advisors LLC在第一季度将其在全球血液治疗公司的股票头寸增加了75.6%。NISA Investment Advisors LLC在此期间又购买了650股,现在拥有1,510股该公司股票,价值52,000美元。Advisor Group Holdings Inc.在第四季度将其在全球血液治疗公司的股票头寸增加了31.8%。Advisor Group Holdings Inc.在此期间又购买了450股,现在拥有1,865股该公司股票,价值55,000美元。Lazard Asset Management LLC在第四季度将其在全球血液治疗公司的股票头寸增加了31.4%。Lazard Asset Management LLC在此期间又购买了617股,现在拥有2579股该公司股票,价值7.5万美元。最后,韦德布什证券公司在第二季度购买了全球血液治疗公司的新股票,价值约20.7万美元。
Global Blood Therapeutics Company Profile
全球血液治疗公司简介
(Get Rating)
(获取评级)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治疗公司是一家生物制药公司,致力于发现、开发和提供针对服务不足的镰状细胞疾病(SCD)患者群体的治疗方法。该公司提供Oxbryta片剂,这是一种治疗SCD的口服药物,每天一次。它还在第二阶段对青少年和儿童SCD患者的临床试验中评估了单剂和多剂Oxbryta的安全性和药代动力学。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免费获取StockNews.com关于全球血液治疗(GBT)的研究报告
- 大型和小型石油和天然气类股盈利后反弹
- 连续十年上涨的两只道指股票
- Rite Aid会再次成为收购目标吗?
- 投资石油股票的方式和原因
- 投资黄金股票的方式和原因
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对全球血液治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。